about
Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imagingX-ray-computed tomography contrast agentsImaging in pancreatic disease.Rapid 3D dynamic arterial spin labeling with a sparse model-based image reconstruction.Gold Nanotheranostics: Proof-of-Concept or Clinical Tool?Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.Protein Nanospheres: Synergistic Nanoplatform-Based Probes for Multimodality Imaging.Amide conjugates of the DO3A-N-(α-amino)propionate ligand: leads for stable, high relaxivity contrast agents for MRI?Bimodal Imaging Using Neodymium Doped Gadolinium Fluoride Nanocrystals with Near-Infrared to Near-Infrared Downconversion Luminescence and Magnetic Resonance Properties.Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress.Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review.Nanoparticle-Based Magnetic Resonance Imaging on Tumor-Associated Macrophages and Inflammation.Multimodality imaging probes: design and challenges.Energy failure in multiple sclerosis and its investigation using MR techniques.Gold-silver alloy nanoshells: a new candidate for nanotherapeutics and diagnostics.Advances in lymphatic imaging and drug delivery.Cancer stratification by molecular imaging.Microcapsules with intrinsic barium radiopacity for immunoprotection and X-ray/CT imaging of pancreatic islet cells.Magnetic Nanoparticles: Material Engineering and Emerging Applications in Lithography and Biomedicine.Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancerMagnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice.Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEBGd-Si Oxide Nanoparticles as Contrast Agents in Magnetic Resonance Imaging.Whole-body MRI in pediatric patients with cancerCurrent and future lymphatic imaging modalities for tumor stagingPET/MR: a paradigm shift.Diagnosis and therapy of atheromatous renal artery stenosis.Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead.Hypoxia in cervical cancer: from biology to imaging.Imaging Carotid Atherosclerosis Plaque Ulceration: Comparison of Advanced Imaging Modalities and Recent Developments.Noninvasive photothermal cancer therapy nanoplatforms via integrating nanomaterials and functional polymers.Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis.Yield of CT Pulmonary Angiography in the Emergency Department When Providers Override Evidence-based Clinical Decision Support.In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform.Synthesis, conjugation and relaxation studies of gadolinium(III)-4-benzothiazol-2-yl-phenylamine as a potential brain specific MR contrast agent.Enhanced cytotoxic and genotoxic effects of gadolinium following ELF-EMF irradiation in human lymphocytes.Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission.Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications.Melanin-manganese nanoparticles with ultrahigh efficient clearance in vivo for tumor-targeting T1 magnetic resonance imaging contrast agent.Shape-dependent cellular behaviors and relaxivity of iron oxide-based T1 MRI contrast agents.
P2860
Q26864381-3AFBEAC6-B570-4559-ACB0-9B2DB843E562Q28280706-16C9A82F-FC24-468A-BC75-9BDBA4A70F36Q30275458-A6E6C374-61F9-405C-A84D-AD2FE03706DFQ30279025-1F6731D3-CD1C-411D-9E0C-43DA2BB92D66Q30360668-A762BD2A-FBCD-40DD-9333-13A5E141D3E7Q30465097-69AF1EDC-E3FA-46A2-AED9-7CB8CA31F939Q30465976-E1CC0D1A-D17F-4E9C-B039-19DC92AB6223Q30575277-4473FD01-BEB4-4B03-AAC7-4F4F6FFD96ECQ30614031-4884EEF9-F5CC-4721-89C8-17543C323A3FQ31031996-BF55112E-6904-4B0A-914B-256DAABE3BBFQ33649756-7A5F0EFA-BC31-473C-8528-D95908FD6713Q33710955-2EED95B7-3768-44D2-B900-BFABEDE4AE22Q33884695-8156B6B3-886F-493B-A465-B9AC3993163CQ33928808-A9CC460A-8767-48FF-854A-C89E7A1DE489Q34047561-8FDC8DF3-8F23-45E1-B5A3-AE79B5ABF73BQ35188498-276A2B4F-BBB2-42AB-93F2-60ACDCBAEB06Q35380664-1A3A932E-07F2-4237-BCF1-C6FA83EE1710Q35903272-6C1ED2AF-0CA3-4EBE-B93D-339891AD916BQ36283461-451F6A6A-F776-44D9-B1F0-839306D628F6Q37139112-97516961-39CF-4BAF-BBCA-03967339E436Q37392147-A476ABFB-C3E0-4388-938F-25074755C86EQ37587773-85DEFB85-7CF2-426B-940B-BB61658E75B3Q37636338-E18E99D0-CB33-4491-9F29-4999695A334BQ37637025-B387A6C4-D5C3-4DFA-813E-308BCBC2EA98Q37686649-090EDB88-6295-4A0F-92F3-BD2F7D209265Q38085153-673B9F3A-6217-4E38-92E7-17853648395DQ38093091-A81B66A5-D99D-44EE-B0CE-F3BD47EE89EEQ38199539-D03508D2-9CA2-423F-8CCB-7175D55DF9FAQ38643119-05CC6F8C-AC56-4381-91F5-F51FA1FE2D1EQ38779071-45A13009-0608-496C-83C2-879F73643327Q38781032-B9BCCF68-02FD-48A3-96E7-ACC333675351Q38922223-F7A18AD5-43FF-40C3-BBBD-7D9F750D687FQ38968896-535EFD05-4058-4271-B04B-73FFD08DA5BAQ41839399-A2EBC0A7-85C4-4FDA-B644-661D192397BDQ46615035-7EDD885D-4F7A-4661-8363-F86E272CB87BQ46938795-32EB29E1-7F09-49DF-A139-756F8E02C12EQ47189782-8C987C3B-21D3-4577-809A-9C019D2D7430Q47589446-6F2112D6-32CA-47FA-925C-D0824A261634Q47767726-39BA9A64-5FBC-4D14-8D83-9B2669A665B4Q48513969-8D1B15EB-2D61-4850-AFCA-A8E0C161F278
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Toxicity of MRI and CT contrast agents
@ast
Toxicity of MRI and CT contrast agents
@en
Toxicity of MRI and CT contrast agents
@en-gb
Toxicity of MRI and CT contrast agents
@nl
type
label
Toxicity of MRI and CT contrast agents
@ast
Toxicity of MRI and CT contrast agents
@en
Toxicity of MRI and CT contrast agents
@en-gb
Toxicity of MRI and CT contrast agents
@nl
prefLabel
Toxicity of MRI and CT contrast agents
@ast
Toxicity of MRI and CT contrast agents
@en
Toxicity of MRI and CT contrast agents
@en-gb
Toxicity of MRI and CT contrast agents
@nl
P2860
P1476
Toxicity of MRI and CT contrast agents
@en
P2093
Kendra M Hasebroock
Natalie J Serkova
P2860
P304
P356
10.1517/17425250902873796
P407
P577
2009-04-01T00:00:00Z